admin – page 7 – eisai china lnc.-威尼斯人888

in the face of the epidemic of covid-19, a large number of patients with normal medical needs can not go to hospital to seek medical treatment, and their diseases can not be treated well, which seriously decreases the quality of life of patients. eisai china holdings ltd. is joining hands with all sectors of society to fight against the epidemic, and escorting people to tide over the crisis. 

for its contributions towards patients with liver disease through the eisai-originated orally available kinase inhibitor lenvima®

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it received the president’s award at the 8th technology management and innovation awards held by the japan techno-economics society (jates)*. the award was presented to eisai for its discovery of the orally available kinase inhibitor lenvima®(generic name: lenvatinib mesylate) and its contributions towards patients with liver disease.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has launched the in-house discovered and developed antiepileptic drug (aed) fycompa®, (product name in china: 卫克泰®, generic name perampanel) for use in adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older.

sysmex corporation (hq: kobe, japan; chairman and ceo: hisashi ietsugu; “sysmex”) and eisai co., ltd. (hq: tokyo, japan; ceo: haruo naito; “eisai”) are pursuing a joint project to develop a method of diagnosing alzheimer’s disease (ad) using blood, presented two posters showing the most recent data from the project. the presentations took place at the 12th clinical trials on alzheimer’s disease (ctad) conference, from december 4 to 7, 2019, in san diego, california. at ctad, sysmex demonstrated on behalf of the two companies the possibility of understanding amyloid pathology in the brain from the brain-derived amyloid beta (aβ) in plasma measured using its protein measurement platform, the hiscl™ series of fully automated immunoassay analyzers.